Clinical Scorecard: Neutrophil-to-lymphocyte ratio as a viable substitute for mHLA-DR assessment in immunosuppression following delayed sepsis
At a Glance
Category
Detail
Condition
Sepsis-induced immunosuppression in critically ill patients
Key Mechanisms
Immuno-inflammatory alterations including neutrophilia, lymphopenia, and decreased monocyte HLA-DR expression
Target Population
Patients with septic shock exhibiting delayed immunosuppression
Care Setting
Intensive Care Unit (ICU)
Key Highlights
Monocyte HLA-DR (mHLA-DR) < 8000 AB/C is a validated biomarker for sepsis-induced immunosuppression but not widely available.
Neutrophil-to-lymphocyte ratio (NLR) > 10 at day 7 post-ICU admission correlates with low mHLA-DR and identifies immunosuppressed patients.
NLR is a practical, universally accessible surrogate marker that integrates neutrophilia, immature neutrophils, and lymphopenia.
Guideline-Based Recommendations
Diagnosis
Use mHLA-DR < 8000 AB/C to identify sepsis-induced immunosuppression when available.
Consider NLR > 10 at day 7 as a provisional marker for immunosuppression in settings lacking mHLA-DR measurement.
Management
Select patients with low mHLA-DR or high NLR for potential immunostimulatory therapies such as interferon-γ.
Use NLR as an alarm parameter to trigger further immunological assessment.
Monitoring & Follow-up
Perform serial mHLA-DR measurements during the first week of ICU admission when possible.
Monitor NLR from routine complete blood counts at day 7 to assess immune status.
Risks
NLR may not accurately assess immunosuppression in patients with profound neutropenia or lymphopenia.
Discordance between NLR and mHLA-DR exists; further investigation is needed to understand underlying mechanisms.
Patient & Prescribing Data
Critically ill septic shock patients with delayed immunosuppression identified by low mHLA-DR or high NLR
Immunostimulatory therapy (e.g., interferon-γ) trials select patients based on mHLA-DR < 8000 AB/C; NLR > 10 may help identify candidates where mHLA-DR is unavailable.
Clinical Best Practices
Incorporate NLR measurement from routine blood counts as a complementary tool to mHLA-DR for immunomonitoring.
Use NLR > 10 as a practical, provisional biomarker to identify patients at risk of immunosuppression and ICU-acquired infections.
Validate NLR thresholds and clinical utility in larger, diverse ICU populations before widespread adoption.
Recognize limitations of NLR in patients with abnormal leukocyte profiles and pursue additional immunological testing as needed.
